Patent intelligence · US
US 10639360
Methods for treating hypophosphatemic disorders
Methods for treating hypophosphatemic disorders
Patent details — US 10639360
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 5, 2020
- Expiration
- Apr 30, 2040
- Applicant
- Ultragenyx Pharmaceutical Inc.
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 10639360 (Methods for treating hypophosphatemic disorders) is held by Ultragenyx Pharmaceutical Inc.. Status: granted. Granted May 5, 2020. Expires Apr 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ultragenyx Pharmaceutical Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K39/001132, A61P
More from Ultragenyx Pharmaceutical Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12358976
Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d
granted -
US 12338450
Gene therapy constructs for treating Wilson disease
granted -
US 11944658
Methods of heat inactivation of adenovirus
granted -
US 11771748
Methods for treating tumor-induced osteomalacia
granted -
US 11753369
Creatine prodrugs, compositions and methods of use thereof
granted -
US 11377643
Therapeutics for glycogen storage disease type III
granted -
US 11332438
Creatine prodrugs, compositions and methods of use thereof
granted -
US 11202822
Methods for treating hypophosphatemic disorders
granted
Frequently asked questions
What is US patent 10639360?
US 10639360 (Methods for treating hypophosphatemic disorders) is held by Ultragenyx Pharmaceutical Inc.. Status: granted. Granted May 5, 2020. Expires Apr 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10639360?
Ultragenyx Pharmaceutical Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 10639360 expire?
Our index shows an expiration date of Apr 30, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.